Publication | Closed Access

The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells

InflammationThrombopoiesisAnti-inflammatoryMedicineHuman Mononuclear CellsImmunologyTumor ImmunityPathologyImmune RegulationImmune FunctionPharmacology